(Bloomberg) -- Keros Therapeutics Inc. shares plunged after the biotech company halted dosing for some patients in a mid-stage trial of its lung disorder drug over side effect concerns.
Shares of Lexington, Massachusetts-based Keros dropped as much as 72% in trading before US markets opened Thursday. If the change holds into regular trading, it will wipe out nearly all gains the stock made this year through Wednesday’s close.
The company voluntarily stopped dosing in two arms of a trial of cibotercept, an experimental treatment for dangerous pulmonary arterial hypertension, according to a statement. Keros made the move after seeing fluid build up around the hearts of some patients.
The study has already reached its patient enrollment goal and will continue dosing patients in one arm, Keros said. It still expects to present data from all the trial’s treatment arms in the second quarter of 2025.
©2024 Bloomberg L.P.
